Silence Therapeutics (SLN) Return on Capital Employed (2021 - 2026)
Silence Therapeutics recorded quarterly Return on Capital Employed of 8.4% in Q1 2026, up 52.4% quarter-over-quarter from 17.65% in Q4 2025, and up 4035.0% year-over-year from 0.2% in Q1 2025.
Silence Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 8.4% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4035.0% year-over-year to 8.4%; the TTM figure through Mar 2026 stood at 8.4% (up 4035.0% YoY), while the FY2025 annual figure was 14.44%, up 2947.0% from the prior year.
- Return on Capital Employed came in at 8.4% for Q1 2026 at Silence Therapeutics, up from 17.65% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.4% in Q1 2026 to a low of 4841425.21% in Q1 2022.
- A 5-year average of 537856.59% and a median of 12.59% in 2024 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 699957478 bps in 2022 and fell as far as 430180653 bps in 2022.
- Silence Therapeutics' Return on Capital Employed stood at 12.76% in 2022, then grew by 3 bps to 12.39% in 2023, then fell by 2 bps to 12.59% in 2024, then slumped by 40 bps to 17.65% in 2025, then surged by 52 bps to 8.4% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 8.4%, 17.65%, and 59.85% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | -8.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.40% |
| Dec 31, 2025 | -17.65% |
| Sep 30, 2025 | -59.85% |
| Jun 30, 2025 | -53.59% |
| Mar 31, 2025 | -48.75% |
| Dec 31, 2024 | -12.59% |
| Sep 30, 2024 | -9.37% |
| Jun 30, 2024 | -8.93% |
| Mar 31, 2024 | -9.46% |
| Dec 31, 2023 | -12.39% |
| Sep 30, 2023 | -11.28% |
| Jun 30, 2023 | -11.12% |
| Mar 31, 2023 | -11.94% |
| Dec 31, 2022 | -12.76% |
| Sep 30, 2022 | -13.70% |
| Jun 30, 2022 | -4,301,835.01% |
| Mar 31, 2022 | -4,841,425.21% |
| Dec 31, 2021 | -6,999,587.55% |
| Sep 30, 2021 | -6,055,235.07% |
| Jun 30, 2021 | -28.49% |